Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants

CONCLUSIONS: Infant vaccination with PCV20 is estimated to further reduce pneumococcal disease and associated healthcare system and societal costs compared to both PCV13 and PCV15.PMID:38191278 | DOI:10.1016/j.vaccine.2023.12.057

Source: Vaccine - January 8, 2024 Category: Allergy & Immunology Authors: Mark H Rozenbaum Liping Huang Johnna Perdrizet Alejandro Cane Adriano Arguedas Kyla Hayford Maria J Tort Ruth Chapman Desmond Dillon-Murphy Vincenza Snow Erica Chilson Raymond A Farkouh Source Type: research